• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嗜铬细胞瘤初次手术后46年发生的迟发性骨转移:一例报告

Late-Onset Bone Metastasis 46 Years After Initial Surgery for Pheochromocytoma: A Case Report.

作者信息

Ishizaki Fumio, Hiruma Kaede, Tani Yusuke, Sugino Hideaki, Sanami Tatsuro, Anraku Tsutomu, Ikeda Masahiro, Tasaki Masayuki, Saito Kazuhide, Tomita Yoshihiko

机构信息

Department of Urology, Molecular Oncology, Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.

Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.

出版信息

IJU Case Rep. 2025 Aug 13;8(5):533-538. doi: 10.1002/iju5.70086. eCollection 2025 Sep.

DOI:10.1002/iju5.70086
PMID:40909300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12408166/
Abstract

INTRODUCTION

Pheochromocytoma is a rare catecholamine-producing tumor with metastatic potential. Recurrence after more than 40 years is exceptionally rare.

CASE PRESENTATION

During evaluation for ischemic colitis, a 71-year-old woman was found to have multiple bone metastases, possibly linked to catecholamine excess. She had undergone left adrenalectomy for pheochromocytoma at age 25. Bone biopsy confirmed metastatic pheochromocytoma, and immunohistochemical findings were similar to the original tumor. Urinary metanephrine and normetanephrine were markedly elevated. She declined systemic therapy and has remained clinically stable for 6 years, with her blood pressure well controlled on doxazosin.

CONCLUSION

This case illustrates a recurrence 46 years after adrenalectomy, potentially representing the longest reported interval to date. It highlights the silent and indolent nature of some metastatic pheochromocytomas and underscores the necessity of lifelong follow-up. The patient's stable course also emphasizes the clinical heterogeneity of metastatic pheochromocytoma and supports the need for individualized follow-up and treatment strategies.

摘要

引言

嗜铬细胞瘤是一种罕见的具有转移潜能的儿茶酚胺分泌肿瘤。40多年后复发极为罕见。

病例介绍

在对一名71岁女性进行缺血性结肠炎评估期间,发现她有多处骨转移,可能与儿茶酚胺过量有关。她25岁时因嗜铬细胞瘤接受了左肾上腺切除术。骨活检证实为转移性嗜铬细胞瘤,免疫组化结果与原发肿瘤相似。尿间甲肾上腺素和去甲间甲肾上腺素明显升高。她拒绝了全身治疗,6年来一直保持临床稳定,服用多沙唑嗪后血压得到良好控制。

结论

本病例显示肾上腺切除术后46年复发,这可能是迄今为止报道的最长间隔时间。它凸显了一些转移性嗜铬细胞瘤的隐匿性和惰性,强调了终身随访的必要性。患者的稳定病程也强调了转移性嗜铬细胞瘤的临床异质性,并支持需要个性化的随访和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/7ba659ba8e8a/IJU5-8-533-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/74ebf3cddb49/IJU5-8-533-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/bd3896780194/IJU5-8-533-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/b55f29ce5476/IJU5-8-533-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/7ba659ba8e8a/IJU5-8-533-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/74ebf3cddb49/IJU5-8-533-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/bd3896780194/IJU5-8-533-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/b55f29ce5476/IJU5-8-533-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea4/12408166/7ba659ba8e8a/IJU5-8-533-g004.jpg

相似文献

1
Late-Onset Bone Metastasis 46 Years After Initial Surgery for Pheochromocytoma: A Case Report.嗜铬细胞瘤初次手术后46年发生的迟发性骨转移:一例报告
IJU Case Rep. 2025 Aug 13;8(5):533-538. doi: 10.1002/iju5.70086. eCollection 2025 Sep.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
6
Assessment of urinary metanephrine and normetanephrine fractionation analyses as aids in the antemortem diagnosis of pheochromocytomas in clouded leopards (Neofelis nebulosa).评估尿间甲肾上腺素和去甲间甲肾上腺素分级分析在云豹(豹猫属)嗜铬细胞瘤生前诊断中的辅助作用。
Am J Vet Res. 2025 Jun 16;86(9). doi: 10.2460/ajvr.25.01.0033. Print 2025 Sep 1.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
9
Hereditary Paraganglioma-Pheochromocytoma Syndromes遗传性副神经节瘤-嗜铬细胞瘤综合征
10
Home versus in-patient treatment for deep vein thrombosis.深静脉血栓形成的家庭治疗与住院治疗对比
Cochrane Database Syst Rev. 2018 Jan 9;1(1):CD003076. doi: 10.1002/14651858.CD003076.pub3.

本文引用的文献

1
Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution.在单一机构的 20 年回顾中,转移性或复发性嗜铬细胞瘤和副神经节瘤的长期结果和预后因素。
Sci Rep. 2024 Nov 2;14(1):26456. doi: 10.1038/s41598-024-75354-9.
2
The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.精准医学时代嗜铬细胞瘤和副神经节瘤的管理:我们现在处于什么阶段?基于证据的系统治疗选择及未来以集群为导向的展望
Pharmaceuticals (Basel). 2024 Mar 8;17(3):354. doi: 10.3390/ph17030354.
3
Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
散发性嗜铬细胞瘤和副神经节瘤患者的复发性疾病。
J Clin Endocrinol Metab. 2023 Jan 17;108(2):397-404. doi: 10.1210/clinem/dgac563.
4
Postoperative Recurrences in Patients Operated for Pheochromocytomas and Paragangliomas: New Data Supporting Lifelong Surveillance.嗜铬细胞瘤和副神经节瘤手术患者的术后复发:支持终身监测的新数据
Cancers (Basel). 2022 Jun 14;14(12):2942. doi: 10.3390/cancers14122942.
5
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.2022 年世卫组织副神经节瘤和嗜铬细胞瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13.
6
Personalized Management of Pheochromocytoma and Paraganglioma.《嗜铬细胞瘤和副神经节瘤的个体化管理》
Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019.
7
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.《嗜铬细胞瘤和副神经节瘤的新视角:迈向分子分类》
Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062.
8
Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.转移性嗜铬细胞瘤和副神经节瘤患者的结局:系统评价和荟萃分析。
Clin Endocrinol (Oxf). 2017 Nov;87(5):440-450. doi: 10.1111/cen.13434. Epub 2017 Aug 17.
9
mutation carriers with malignant pheochromocytoma respond better to CVD.患有恶性嗜铬细胞瘤的突变携带者对心血管疾病(CVD)的反应更好。
Endocr Relat Cancer. 2017 Aug;24(8):L51-L55. doi: 10.1530/ERC-17-0086. Epub 2017 May 31.
10
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.2017 年世界卫生组织(WHO)内分泌肿瘤学肾上腺肿瘤更新。
Endocr Pathol. 2017 Sep;28(3):213-227. doi: 10.1007/s12022-017-9484-5.